JNJ delivered favorable financial results at the year-end of 2021, with its growth substantially larger than that of competitors. With its steadily growing EPS, the company's dividend yield of 2.57% stands significantly above the S&P 500 average of 1.57%, adding to the reasons why JNJ is a clear market favorite.
Johnson & Johnson - Hold
Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of B.
JNJ 178.14 -1.38(-0.77%)
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that nearly triples the S&P 500.
The intrinsic value of one JNJ stock under the Base Case scenario is 138.42 USD. Compared to the current market price of 178.23 USD, Johnson & Johnson is Overvalued by 22%.
Procter & Gamble has received a consensus rating of Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.
J&J itself isn't bankrupt—instead, it has split off a new unit essentially designed to go broke paying legal liabilities. It's part of a maneuver to deal with about 38,000 lawsuits, mostly filed by women who claim one of the company's oldest products, baby powder, causes ovarian cancer.
The split isn't expected to happen until the end of 2023. Duato also told investors that the pandemic sped up trends like same-day delivery within the consumer health business.
Along with the results, JNJ also announced a hike in its quarterly dividend by 6.6%, to $1.13 per share. This marks the company's 60th consecutive yearly dividend increase. The company's efforts in growing its business through new innovative products and drugs are why I believe Johnson & Johnson is worth investing in.
JNJ's strong financial fundamentals and its market position make it a highly secure option, with its diversified segments that result in a minimized risk exposure for the company.
So in terms of key growth measures, JNJ stock outranks 94% of all stocks. (Related: Does your favorite stock get a pass or fail rating from IBD Digital?) J&J stock has an IBD Relative Strength Rating of 92. The RS Rating measures a stock's 12-month performance on a 1-99 scale against all other stocks.
19. Rachel Warren: If you currently own shares of Johnson & Johnson like I do, when the company splits, you will own shares of both Johnson & Johnson, the new pharmaceutical/medical device entity, as well as the new yet-to-be-named consumer health business.
Summary. Looking at blue-chip stocks, JNJ presents as the best value buying by a long way, headlining with a P/E valuation discount of 41.9% to it's peers by market cap.
Johnson & Johnson traces its roots to a health products company formed by Robert Wood Johnson and his brothers. The company joins Toshiba and General Electric, which also announced they are breaking up their companies to focus on more profitable business units.
Johnson & Johnson announced yesterday that it was buying the Pfizer division, paying $16.6 billion to beat out several other bidders. Analysts said the move would make Johnson & Johnson the world's largest consumer health care company.
Johnson & Johnson Named to Glassdoor's 2018 List of Best Places to Work Johnson & Johnson Named to Glassdoor's 2018 List of Best Places to Work. The company nabbed a top spot on the annual list—based entirely on positive reviews from its own employees.
Johnson & Johnson Announces $5 Billion Share Repurchase Program | Johnson & Johnson. New Brunswick, NJ (December 17, 2018) – Johnson & Johnson (NYSE: JNJ) today announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock.
Stock Price Forecast
The 17 analysts offering 12-month price forecasts for Johnson & Johnson have a median target of 187.00, with a high estimate of 215.00 and a low estimate of 174.00. The median estimate represents a +9.04% increase from the last price of 171.50.
Johnson & Johnson announced in November that it plans to spin off its consumer business into a new publicly traded company by November 2023. The news didn't surprise Wall Street. “The analyst community has been talking about splitting up J&J for years,” said Jared Holz, health-care equity strategist at Oppenheimer.
According to our Johnson and Johnson stock split history records, Johnson and Johnson has had 6 splits.